DOCSLIB.ORG

New Alliance with Gilead Sciences Is 'Transformative'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Alliance with Gilead Sciences Is 'Transformative' May/June 2011 volume 7, issue 2 Advancing Biomedical Science, Education, and Health Care New alliance with Gilead Sciences is ‘transformative’ Research collaboration pairs Yale experts To begin to bend this troubling curve, some phar- maceutical companies have been building scientific with industry scientists to accelerate the alliances with universities, a trend that has picked up development of new drugs to treat cancer steam during the past few years. In March, President Richard C. Levin announced that Yale University When Robert J. Alpern, m.d., dean of the School had forged a multi-year research alliance with Gilead of Medicine, was asked recently to prepare a brief Sciences, Inc., a biopharmaceutical company based overview of the current state of drug discovery for a in Foster City, Calif., to accelerate the discovery and symposium at Yale’s West Campus, a familiar phrase development of new drugs to treat cancer. came quickly to mind: “It was the best of times, it was Gilead will provide up to $40 million to support the worst of times . ” cancer research at the School of Medicine over four It’s an apt description. On the one hand, we live in years, and a total of up to $100 million—the largest what some call the “post-Gleevec era,” a time when ba- corporate commitment in Yale’s history—for the full sic research conducted over decades is bearing fruit in 10 years outlined in the agreement. Yale maintains the form of remarkably effective, targeted drugs. But ownership of all intellectual property generated by the cost of drug development has risen exponentially medical school research, and Gilead will have the first as clinical trials and regulations have grown more option to develop any compound it deems promising. complex. The average total cost to develop a single ap- “The collaboration brings together one of the proved drug is now pegged at a staggering $1.3 billion, world’s top research universities and a biopharma- a 60 percent increase since 2005. ceutical company dedicated to addressing unmet courtesy of gilead sciences Early-stage research carried out by academic scien- medical needs, with the goal of finding new treat- Prime movers at Gilead Sciences in the new initiative with the tists in settings like the School of Medicine is unveiling ments for cancer,” Levin said. “This truly is transfor- School of Medicine are (clockwise from left) Howard Jaffe, a 1982 more potential drug targets than ever. But research mative support that leverages Yale Cancer Center’s alumnus of the medical school and president and chairman of the grants are not designed to sustain the many addi- top scientists, our West Campus technology invest- board of the Gilead Foundation; Linda Slanec Higgins, vice presi- dent, Biology; and William Lee, senior vice president, Research. tional steps involved in drug discovery, and academic ments, and the resources of the new Smilow Cancer researchers lack resources to explore these targets fur- Hospital. I can’t think of a better partner to have in Medical Institute investigator, and Thomas J. Lynch ther. The expense and complexity of bringing drugs to this collaboration than Gilead.” Jr., m.d., the Richard Sackler and Jonathan Sack- the marketplace have understandably made phar- The project will be governed by a six-member ler Professor of Medicine, director of Yale Cancer maceutical companies risk-averse and selective about Joint Steering Committee chaired by Joseph “Yossi” Center, and physician-in-chief at Smilow Cancer which targets to pursue. The resulting gap between Schlessinger, ph.d., chair and William H. Prusoff Hospital. They will be joined by Gilead scientists academia and industry has become known as the Val- Professor of Pharmacology at the School of Medi- Howard Jaffe, m.d., a 1982 alumnus of the School of ley of Death: only a miniscule number of promising cine. The committee will also include medical school Medicine and president and chairman of the board discoveries manage to traverse this chasm, and even scientists Richard P. Lifton, m.d., ph.d., chair and of the Gilead Foundation; William A. Lee, ph.d., fewer result in drugs approved for clinical use. Sterling Professor of Genetics and Howard Hughes senior vice president, research; and // Gilead (page 8) Donation from leading Asian foundation will advance stem cell science The Li Ka Shing Foundation (lksf), to continue to make of Medicine in 2010. “The team at Yale cells—but, like hescs, they can self- Asia’s largest philanthropic organiza- available to its seems to be very open, and wants to regenerate indefinitely and can develop tion, has made a $1.5 million donation members the most support and leverage each other’s work into any kind of bodily cell or tissue. to the Yale Stem Cell Center (yscc). current technolo- to accelerate science. At the Stem Cell Because ipscs are genetically matched The donation will fund improvements gies used in stem Center, I felt that Haifan has developed to the donor, they may not induce a in two of the yscc’s four core laborato- cell research.” a unique sense of community and rejection response by the immune ries that will benefit the work of more YSCC Director bonding between the different teams.” system, an important characteristic in than 60 faculty members and numer- Haifan Lin, ph.d., In the yscc’s human embryonic developing personalized treatments for ous trainees across the campus. Li Ka-shing professor of cell stem cell (hesc) facility, the dona- individual patients. In announcing the contribution, biology, first met LKSF Director Solina tion will support the introduction of The new ipsc initiative at the Yale University President Richard C. Chau during a trip to Hong Kong last induced pluripotent stem cell (ipsc) yscc will be supervised by In-Hyun Levin said, “We are grateful for the year, but Chau says it was more than technology, which will bring scientists Park, ph.d., assistant professor of Li Ka Shing Foundation’s generos- the proposal on behalf of the yscc Lin closer to tailoring patient-specific cells genetics, one of the world’s first ity, which benefits today’s medical sent later that won lksf’s support. for the treatment of disease. scientists to develop ipsc technology. research in order to develop tomor- “We have all been great admirers of Discovered in 2006, ipscs are Park’s work has focused on the basic row’s cures. This significant donation the work of Yale for 100 years in Chi- typically derived from ordinary adult biology of stem cells and on the use will allow the Yale Stem Cell Center na,” says Chau, who visited the School cells such as skin cells—not embryonic of stem cells to // Li Ka Shing (page 7) Non-Profit Org. inside this issue 1 Church St., Suite 300, New Haven, CT 06510-3330 U. S. Postage www.medicineatyale.org 2 Lifelines paid Brian Smith discusses how far laboratory New Haven, CT medicine has come—and where it’s headed. Permit No. 526 3 Meeting of the minds School of Medicine’s April symposium, “Biomedicine in the New Century,” draws top-notch speakers and enthusiastic crowds. 8 Given in gratitude Herbert and Marigrace Boyer are honored with the medical school’s highest honor, the Peter Parker Medal, for their generosity. also Advances, pp. 3, 5 Out & About, p. 4 Grants and Contracts, p. 6 lifelines Translational work by diabetes expert is cited in award Brian Smith, who leads the medical school’s Department William V. Tam- of Laboratory Medicine, borlane, m.d., says that the technologies professor of that are making personal- ized medicine a reality pose pediatrics and a daunting challenges to his world-renowned field. The sheer quantity of figure in the patient information that understanding can now be obtained from and treatment genomic analysis and other techniques raises a William of childhood multitude of practical and Tamborlane diabetes, has ethical questions, and will been awarded require informatics experts the T2-Translation Award by the to devise innovative ways to Society for Clinical and Transla- manage and interpret highly complex data. tional Science (scts). The award recognizes the trans- lation of research from early clinical Brian Smith use to applicability for widespread harold shapiro harold clinical practice. The award honors Tamborlane’s pioneering clini- cal research, which has led to new delivery methods for physiological Tackling an information explosion replacement of insulin, preventing Chair worries that the U.S. has explored the interface between genome, has brought formidable chal- many of the major long-term com- the immune and coagulation (clotting) lenges to laboratory medicine. plications of childhood diabetes. is not ready for the coming systems in blood diseases, cardiovascu- Labs will soon routinely perform Tamborlane is chief of the Sec- deluge of medical data lar disorders, and metastatic cancer. His complex genomic and proteomic tion of Pediatric Endocrinology and work on these two critical physiologies analyses impossible just a few years ago, deputy director of the Yale Center For a leader in a field at a pivotal may ultimately help to reduce com- vastly improving diagnosis but increas- for Clinical Investigation. His moment of transition, Brian R. Smith, plications associated with heart-lung ing reliance on informatics. “Humans are major achievements have included m.d., is modest, equating his role as bypass machines and the administra- very good at some qualitative pattern pioneering work in the development chair of the Department of Laboratory tion of blood transfusions. recognition, but computers are far of insulin pump therapy, continu- Medicine to mostly “filling out pieces of After attending Princeton as an better at consolidating multiple quan- ous glucose monitoring, sensor- paper.” But Smith’s department, with a undergraduate, Smith received his titative analyses for diagnostics or fol- augmented pumps, and a prototype mission that combines both service and m.d.
Load more

Recommended publications
  • RANDY SCHEKMAN Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, USA
    GENES AND PROTEINS THAT CONTROL THE SECRETORY PATHWAY Nobel Lecture, 7 December 2013 by RANDY SCHEKMAN Department of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, USA. Introduction George Palade shared the 1974 Nobel Prize with Albert Claude and Christian de Duve for their pioneering work in the characterization of organelles interrelated by the process of secretion in mammalian cells and tissues. These three scholars established the modern field of cell biology and the tools of cell fractionation and thin section transmission electron microscopy. It was Palade’s genius in particular that revealed the organization of the secretory pathway. He discovered the ribosome and showed that it was poised on the surface of the endoplasmic reticulum (ER) where it engaged in the vectorial translocation of newly synthesized secretory polypeptides (1). And in a most elegant and technically challenging investigation, his group employed radioactive amino acids in a pulse-chase regimen to show by autoradiograpic exposure of thin sections on a photographic emulsion that secretory proteins progress in sequence from the ER through the Golgi apparatus into secretory granules, which then discharge their cargo by membrane fusion at the cell surface (1). He documented the role of vesicles as carriers of cargo between compartments and he formulated the hypothesis that membranes template their own production rather than form by a process of de novo biogenesis (1). As a university student I was ignorant of the important developments in cell biology; however, I learned of Palade’s work during my first year of graduate school in the Stanford biochemistry department.
    [Show full text]
  • Meet the Faculty Candidates
    MEET THE FACULTY CANDIDATES Candidates are displayed in alphabetically by last name. Prospective employers are invited to attend and while no event pre-registration is required however they must be registered for the BMES 2018 Annual Meeting. A business card will be required to enter the event. COMPLETE DETAILED CANDIDATE INFORMATION AVAILABLE AT www.bmes.org/faculty. Specialty - Biomaterials Alessia Battigelli Woo-Sik Jang Sejin Son John Clegg Patrick Jurney Young Hye Song R. Cornelison Kevin McHugh Ryan Stowers Yonghui Ding Yifeng Peng Varadraj Vernekar Victor Hernandez-Gordillo Shantanu Pradhan Scott Wilson Marian Hettiaratchi Eiji Saito Yaoying Wu Era Jain Andrew Shoffstall Specialty - Biomechanics Adam Abraham Vince Fiore Panagiotis Mistriotis Edward Bonnevie Zeinab Hajjarian Simone Rossi Alexander Caulk Xiao Hu Alireza Yazdani Venkat Keshav Chivukula Heidi Kloefkorn Rana Zakerzadeh Jacopo Ferruzzi Yizeng Li Specialty - Biomedical Imaging Mahdi Bayat Chong Huang Katheryne Wilson Zhichao Fan Jingfei Liu Kihwan Han Alexandra Walsh Specialty - BioMEMS Jaehwan Jung Aniruddh Sarkar Mengxi Wu Specialty - Cardiovascular Engineering Reza Avaz Kristin French Zhenglun (Alan) Wei Specialty - Cellular Engineering Annie Bowles Kate Galloway Kuei-Chun Wang Alexander Buffone Laurel Hind Mahsa Dabagh Matthew Kutys See other side for more candidates Specialty - Device Engineering (Microfluidics, Electronics, Machine-Body interface) Taslim Al-Hilal Brian Johnson David Myers Jungil Choi Tae Jin Kim Max Villa Haishui Huang Jiannan Li Ying Wang Specialty
    [Show full text]
  • Elaine Fuchs
    Women in Cell Science 4877 Elaine Fuchs FMW: How has your research career impacted on your personal life and vice Elaine Fuchs was born in the United versa? States and raised just outside Chicago. In 1972 she graduated with EF: My father was a geochemist who a B.S. and highest distinction in specialized in meteorites at Argonne the Chemical Sciences from the National Laboratories. My aunt, who University of Illinois. Her lived in the house next door, was a undergraduate thesis research in biologist at Argonne, and an ardent physical chemistry focused on the feminist. My sister, four years my senior, electrodiffusion of nickel through is now a neuroscientist. My mother is a quartz. She moved from Illinois to housewife, who loves gardening and Princeton University to study for her cooking and used to play piano and paint PhD in Biochemistry, investigating in oils. Growing up in such a family, and changes in bacterial cell walls during with farm fields, creeks and ponds in the sporulation in Bacillus megaterium. near vicinity, I developed a deep interest Elaine Fuchs in her lab in 1980. In 1977, she joined Howard Green, in science that has carried me through then at Massachusetts Institute my professional life. of Technology (MIT), for her If I think back to the family influences during Vietnam War protests. Although postdoctoral studies. There, she that shaped my choice of career, I my near perfect performances on tough focused on elucidating the remember that my Dad strongly physics and chemistry exams may have mechanisms underlying the balance advocated my being an elementary turned a few heads, I don’t feel that it between growth and differentiation in school teacher.
    [Show full text]
  • A Short History of DNA Technology 1865 - Gregor Mendel the Father of Genetics
    A Short History of DNA Technology 1865 - Gregor Mendel The Father of Genetics The Augustinian monastery in old Brno, Moravia 1865 - Gregor Mendel • Law of Segregation • Law of Independent Assortment • Law of Dominance 1865 1915 - T.H. Morgan Genetics of Drosophila • Short generation time • Easy to maintain • Only 4 pairs of chromosomes 1865 1915 - T.H. Morgan •Genes located on chromosomes •Sex-linked inheritance wild type mutant •Gene linkage 0 •Recombination long aristae short aristae •Genetic mapping gray black body 48.5 body (cross-over maps) 57.5 red eyes cinnabar eyes 67.0 normal wings vestigial wings 104.5 red eyes brown eyes 1865 1928 - Frederick Griffith “Rough” colonies “Smooth” colonies Transformation of Streptococcus pneumoniae Living Living Heat killed Heat killed S cells mixed S cells R cells S cells with living R cells capsule Living S cells in blood Bacterial sample from dead mouse Strain Injection Results 1865 Beadle & Tatum - 1941 One Gene - One Enzyme Hypothesis Neurospora crassa Ascus Ascospores placed X-rays Fruiting on complete body medium All grow Minimal + amino acids No growth Minimal Minimal + vitamins in mutants Fragments placed on minimal medium Minimal plus: Mutant deficient in enzyme that synthesizes arginine Cys Glu Arg Lys His 1865 Beadle & Tatum - 1941 Gene A Gene B Gene C Minimal Medium + Citruline + Arginine + Ornithine Wild type PrecursorEnz A OrnithineEnz B CitrulineEnz C Arginine Metabolic block Class I Precursor OrnithineEnz B CitrulineEnz C Arginine Mutants Class II Mutants PrecursorEnz A Ornithine
    [Show full text]
  • Schedule of C Ourses
    2017–2018 Schedule of Courses Schedule The David Rockefeller Graduate Program offers a Required reading: Molecular Biology of the Cell by Bruce Alberts et al.; Molecular Cell Biology by James E. Darnell et al. selection of courses, many of which students can Recommended reading: Basic Histology by Luiz Carlos Junqueira choose based on their interests and area of thesis et al. research. Organized by Rockefeller faculty, and taught Method of evaluation: Attendance, participation in the discussions, by scientists at the top of their fields, both from within student presentations, and a final oral exam and outside of the university, these courses are designed to provide a stimulating and dynamic curriculum that Cell Cycle Control students can tailor to fit their personal goals, in FREDERICK R. CROSS and HIRONORI FUNABIKI consultation with the dean of graduate studies. This seminar explores the current understanding of eukaryotic cell cycle control. Topics include the construction of a biochemical oscillator and overall structure of cell cycle control; positive and Biochemical and Biophysical Methods negative control of DNA replication; spindle morphogenesis and function; chromosome cohesion control; surveillance mechanisms SETH A. DARST and MICHAEL P. ROUT (checkpoints) monitoring spindle and DNA integrity; and control of This course presents the fundamental principles of biochemistry proliferation (start/restriction point control). The seminar relies heavily and biophysics, with an emphasis on methodologies. It addresses on studies in model organisms, but the emphasis throughout will be issues of protein and nucleic acid structure and the forces that on aspects of cell cycle control conserved among eukaryotes. underlie stability and govern the formation of specific three- Class length and frequency: 2.5-hour lecture and discussion, dimensional structures.
    [Show full text]
  • Hhmi Bulletin 3 4 Hhmi Club
    HHMI BULLETIN 4000 Jones Bridge Road • Chevy Chase, Maryland 20815-6789 Howard Hughes Medical Institute www.hhmi.org One Lump or Two? in this issue Once again, those fast-growing yeast find a way to turn a The Silicon Marvel long-held theory on its head. This time, it’s about prions, • Prions for Good which aren’t as universally nasty as once suspected. Some may actually help organisms evolve. The yeast colony shown here www.hhmi.org A Kaleidoscopic View contains a protein in its prion form. Because the prion, known as PSI+, is self-replicating and forms fibrous amyloids, the yeast look lumpy and bumpy—strikingly different from normally smooth yeast. Susan Lindquist’s group has found 19 yeast proteins that can switch back and forth between a normal and a prion version. The prions are thought to help the yeast adapt to changing conditions (see “A Silver Lining,” page 22). LIGHT MOVES v ol. 23 Heather True / Lindquist lab /no. 02 O b s e r v a t i O n s 16 Secret Agent MAn Skin cells do more than just cover our bodies. As a neurology resident, Stanley Prusiner saw Creutzfeldt–Jakob agent began to emerge. These data established, for the first time, that Keratinocytes, for example, anchor immune cells disease kill a patient in a matter of months. Researchers knew the rare a particular macromolecule was required for infectivity and that this within the epidermis, move and proliferate during neurodegenerative disease and scrapie, a similar disease in sheep, macromolecule was a protein …. wound healing, and even secrete inhibitory molecules were infectious but not as a result of a typical virus.
    [Show full text]
  • Humankind 2.0: the Technologies of the Future 6. Biotech
    Humankind 2.0: The Technologies of the Future 6. Biotech Piero Scaruffi, 2017 See http://www.scaruffi.com/singular/human20.html for the full text of this discussion A brief History of Biotech 1953: Discovery of the structure of the DNA 2 A brief History of Biotech 1969: Jon Beckwith isolates a gene 1973: Stanley Cohen and Herbert Boyer create the first recombinant DNA organism 1974: Waclaw Szybalski coins the term "synthetic biology” 1975: Paul Berg organizes the Asilomar conference on recombinant DNA 3 A brief History of Biotech 1976: Genentech is founded 1977: Fred Sanger invents a method for rapid DNA sequencing and publishes the first full DNA genome of a living being Janet Rossant creates a chimera combining two mice species 1980: Genentech’s IPO, first biotech IPO 4 A brief History of Biotech 1982: The first biotech drug, Humulin, is approved for sale (Eli Lilly + Genentech) 1983: Kary Mullis invents the polymerase chain reaction (PCR) for copying genes 1986: Leroy Hood invents a way to automate gene sequencing 1986: Mario Capecchi performs gene editing on a mouse 1990: William French Anderson’s gene therapy 1990: First baby born via PGD (Alan Handyside’s lab) 5 A brief History of Biotech 1994: FlavrSavr Tomato 1994: Maria Jasin’s homing endonucleases for genome editing 1996: Srinivasan Chandrasegaran’s ZFN method for genome editing 1996: Ian Wilmut clones the first mammal, the sheep Dolly 1997: Dennis Lo detects fetal DNA in the mother’s blood 2000: George Davey Smith introduces Mendelian randomization 6 A brief History of Biotech
    [Show full text]
  • Guide to Biotechnology 2008
    guide to biotechnology 2008 research & development health bioethics innovate industrial & environmental food & agriculture biodefense Biotechnology Industry Organization 1201 Maryland Avenue, SW imagine Suite 900 Washington, DC 20024 intellectual property 202.962.9200 (phone) 202.488.6301 (fax) bio.org inform bio.org The Guide to Biotechnology is compiled by the Biotechnology Industry Organization (BIO) Editors Roxanna Guilford-Blake Debbie Strickland Contributors BIO Staff table of Contents Biotechnology: A Collection of Technologies 1 Regenerative Medicine ................................................. 36 What Is Biotechnology? .................................................. 1 Vaccines ....................................................................... 37 Cells and Biological Molecules ........................................ 1 Plant-Made Pharmaceuticals ........................................ 37 Therapeutic Development Overview .............................. 38 Biotechnology Industry Facts 2 Market Capitalization, 1994–2006 .................................. 3 Agricultural Production Applications 41 U.S. Biotech Industry Statistics: 1995–2006 ................... 3 Crop Biotechnology ...................................................... 41 U.S. Public Companies by Region, 2006 ........................ 4 Forest Biotechnology .................................................... 44 Total Financing, 1998–2007 (in billions of U.S. dollars) .... 4 Animal Biotechnology ................................................... 45 Biotech
    [Show full text]
  • Phi Beta Kappa Visiting Scholars 1956-57- 2016-2017 (61 Years)
    Phi Beta Kappa Visiting Scholars 1956-57- 2016-2017 (61 years) 2016-2017 (112 visits) Adorno, Rolena Spanish/Latin American literatur Yale Bialek, William physics Princeton Ehrman, Bart D. religion, New Testament UNC-Chapel Hill Grosz, Barbara J. computer science Harvard Hochschild, Jennifer L. political science Harvard Kitcher, Philip philosophy Columbia Lester, Marsha I. chemistry Penn Morse, Nora Naranjo fine arts, poetry, sculpture Espanola, NM Rodgers, Daniel T. American history & culture Princeton Sabloff, Jeremy A. anthropology, Maya Penn Weiman, David F. economic history Barnard Wexler, Laura American studies Yale Witt, John Fabian law, American history Yale Wright, Patricia anthropology/primatology SUNY, Stony Brook Xiao, Shuhai geobiology/paleobiology Virginia Tech 2015-2016 (100 visits) Michael Bérubé English, disability studies Penn State Caroline Bruzelius art, art history Duke David K. Campbell physics, engineering Boston U. Hazel V. Carby African American studies Yale Carol Greenhouse anthropology, sociocultural Princeton David B. Grusky sociology, inequality, poverty Stanford Rigoberto Hernandez biochemistry, diversity studies Georgia Tech Mae Ngai history, Asian American studies Columbia Judith Resnik law Yale Timothy Rowe paleontology, geology UTAustin Larry A. Silver art history, Renaissance Penn Harold W. Stanley political science, elections Southern Methodist Richard Sylla American economic history NYU Blaire Van Valkenburgh vertebrate paleonbiology UCLA Vincent L. Wimbush religion Inst.SignifyingScriptures 2014-2015 (96 visits) Jeffrey C. Alexander sociology Yale William Y. Arms computer science Cornell Wendy Brown political science UCBerkeley Caroline Bruzelius art, art history Duke Philip J. Deloria history, American Indian Michigan Gerald Graff English, education Illinois at Chicago Kathleen McGarry economics, aging UCLA Gregory A. Petsko neurology, neuroscience Cornell Med.
    [Show full text]
  • Documenting the Biotechnology Industry in the San Francisco Bay Area
    Documenting the Biotechnology Industry In the San Francisco Bay Area Robin L. Chandler Head, Archives and Special Collections UCSF Library and Center for Knowledge Management 1997 1 Table of Contents Project Goals……………………………………………………………………….p. 3 Participants Interviewed………………………………………………………….p. 4 I. Documenting Biotechnology in the San Francisco Bay Area……………..p. 5 The Emergence of An Industry Developments at the University of California since the mid-1970s Developments in Biotech Companies since mid-1970s Collaborations between Universities and Biotech Companies University Training Programs Preparing Students for Careers in the Biotechnology Industry II. Appraisal Guidelines for Records Generated by Scientists in the University and the Biotechnology Industry………………………. p. 33 Why Preserve the Records of Biotechnology? Research Records to Preserve Records Management at the University of California Records Keeping at Biotech Companies III. Collecting and Preserving Records in Biotechnology…………………….p. 48 Potential Users of Biotechnology Archives Approaches to Documenting the Field of Biotechnology Project Recommendations 2 Project Goals The University of California, San Francisco (UCSF) Library & Center for Knowledge Management and the Bancroft Library at the University of California, Berkeley (UCB) are collaborating in a year-long project beginning in December 1996 to document the impact of biotechnology in the Bay Area. The collaborative effort is focused upon the development of an archival collecting model for the field of biotechnology to acquire original papers, manuscripts and records from selected individuals, organizations and corporations as well as coordinating with the effort to capture oral history interviews with many biotechnology pioneers. This project combines the strengths of the existing UCSF Biotechnology Archives and the UCB Program in the History of the Biological Sciences and Biotechnology and will contribute to an overall picture of the growth and impact of biotechnology in the Bay Area.
    [Show full text]
  • Elaine Fuchs
    Elaine Fuchs Date of Birth 5 May 1950 Place Illinois, USA Nomination 27 March 2018 Field Stem cell and cancer biology Title Investigator of the Howard Hughes Medical Institute and Rebecca C. Lancefield Professor of the Rockefeller University Professional address Howard Hughes Medical Institute The Rockefeller University 1230 York Avenue, Box 300 New York, NY 10065 USA Most important awards, prizes and academies Academic qualifications: University of Illinois, B.S. Chemistry, 1972, Highest distinction in the curriculum; Princeton University, Ph.D., Biochemistry, 1977; Massachusetts Inst. Technology, Postdoctoral Fellow, 1977-80. Academies: American Academy of Arts and Sciences (‘94); National Academy of Medicine (‘94); National Academy of Sciences (‘96); American Philosophical Society (‘05); EMBO Foreign Member (’10); Academy of the American Association for Cancer Research ('13); Academy of the American Society for Cell Biology (’16). Major Elected Posts in National/International Societies: President, American Society for Cell Biology, '01; National Academy of Sciences, Council '01-'04; President, Harvey Society, '07; President, International Society for Stem Cell Research (ISSCR), '10; New York Academy of Sciences Board of Governors ('11-); National Academy of Medicine, Council ('14-). Honours: University of Illinois 1968-1972: Phi Beta Kappa; Agnes Sloan Larson Award; Iota Sigma Pi Award; Reynold Clayton Fuson Award; James Scholar; Bronze Tablet (top 3% Graduating Class). Massachusetts Institute of Technology 1977-1979: Damon Runyon Postdoctoral Fellow. University of Chicago 1980-2002: Searle Scholar ('81-'83); Presidential Young Investigator Award ('84-'89); Montagna Award (Society for Investigative Dermatology, '95); Senior Women's Career Achievement Award (American Society for Cell Biology '97); Richard Lounsbery Award (National Academy of Sciences, '01).
    [Show full text]
  • Mary Elizabeth Hatten
    Mary Elizabeth Hatten BORN: Richmond, Virginia February 1, 1950 EDUCATION: Hollins College, Roanoke, VA, AB (1971) Princeton University, Princeton, NJ, PhD (1975) Harvard Medical School, Boston, MA, Postdoctoral (1978) APPOINTMENTS: Assistant Professor of Pharmacology, New York University School of Medicine (1978–1982) Associate Professor of Pharmacology (with tenure), New York University School of Medicine (1982–1986) Associate Professor of Pathology in the Center for Neurobiology and Behavior College of Physicians and Surgeons of Columbia University (1986–1988) Professor of Pathology in the Center for Neurobiology and Behavior College of Physicians and Surgeons of Columbia University (1988–1992) Professor and Head of the Laboratory of Developmental Neurobiology, The Rockefeller University (1992–2000) Frederick P. Rose Professor and Head of the Laboratory of Developmental Neurobiology, The Rockefeller University (2000–present) HONORS AND AWARDS (SELECTED): Westinghouse National Science Talent Search Award Finalist (1967) Research Fellow of the Alfred P. Sloan Foundation (1983–1985) Pew Neuroscience Award (1988–1992) McKnight Neuroscience Development Award (1991–1993) Javits Neuroscience Investigator Award (1991–1998) National Science Foundation Faculty Award for Women Scientists and Engineers (1991–1996) Weill Award, American Association of Neuropathology (1996) Ph.D., Hollins College, honoris causa (1998) Fellow, American Association for the Advancement of Science (2002) Distinguished Alumna Award, Hollins University (2011) Cowan-Cajal Award for Developmental Neuroscience (2015) Elected to National Academy of Sciences, USA (2017) Ralph J. Gerard Prize in Neuroscience, Society for Neuroscience (2017) Mary E. Hatten has used the mouse cerebellar cortex as a model to study molecular mechanisms of central nervous system (CNS) cortical neurogenesis and migration. She pioneered live imaging methods that proved that CNS neurons migrate on glial fibers and revealed a specific, conserved mode of CNS neuronal migration along glial fibers in different cortical regions.
    [Show full text]